Stockreport

FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)

FSD Pharma Inc. - Class B Subordinate Voting Shares  (HUGE) 
PDF TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the "Company") today announced receipt of approval from the Ethics [Read more]